These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23174090)

  • 41. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.
    Bauer M; McIntyre RS; Szamosi J; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1755-65. PubMed ID: 23672772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
    Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
    Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
    Huang CC; Wei IH; Huang CL; Chen KT; Tsai MH; Tsai P; Tun R; Huang KH; Chang YC; Lane HY; Tsai GE
    Biol Psychiatry; 2013 Nov; 74(10):734-41. PubMed ID: 23562005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
    Schüle C; Baghai TC; Eser D; Hecht S; Hermisson I; Born C; Häfner S; Nothdurfter C; Rupprecht R
    World J Biol Psychiatry; 2007; 8(2):112-22. PubMed ID: 17455104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
    Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
    Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder.
    Heresco-Levy U; Kremer I; Javitt DC; Goichman R; Reshef A; Blanaru M; Cohen T
    Int J Neuropsychopharmacol; 2002 Dec; 5(4):301-7. PubMed ID: 12466030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence.
    Krystal JH; Petrakis IL; Limoncelli D; Nappi SK; Trevisan L; Pittman B; D'Souza DC; Suckow RF
    Neuropsychopharmacology; 2011 Feb; 36(3):701-10. PubMed ID: 21124304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study.
    Dong Z; Grunebaum MF; Lan MJ; Wagner V; Choo TH; Milak MS; Sobeih T; Mann JJ; Kantrowitz JT
    Front Psychiatry; 2021; 12():653026. PubMed ID: 34149476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapy refractory depression: symptom improvement after antidepressant and methylphenidate combination therapy].
    Niederhofer H
    Wien Med Wochenschr; 2002; 152(21-22):578-80. PubMed ID: 12506683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. D-cycloserine is not susceptible to self-administration using an intravenous self-administration model in male ketamine-habituated Sprague-Dawley rats.
    Sapko MT; Hanania T; Chang Q; Javitt JC
    Pharmacol Biochem Behav; 2023 Jun; 227-228():173586. PubMed ID: 37330114
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of ketamine and D-cycloserine on the high frequency resting EEG spectrum in humans.
    Nottage JF; Gabay A; De Meyer K; Herrik KF; Bastlund JF; Christensen SR; Gijsen S; Mehta MA
    Psychopharmacology (Berl); 2023 Jan; 240(1):59-75. PubMed ID: 36401646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.
    Heresco-Levy U; Lerer B
    Mol Psychiatry; 2024 Jan; 29(1):146-152. PubMed ID: 37945694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-Dose d-Cycloserine for Depression?
    Kim SW; Kushner MG; Yoon G; Anker J; Grant JE
    J Clin Psychiatry; 2016 Aug; 77(8):e1007. PubMed ID: 27561144
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.